Deutsche Bank AG Invests $3.16 Million in Evolus, Inc. $EOLS

Deutsche Bank AG acquired a new stake in shares of Evolus, Inc. (NASDAQ:EOLS) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 454,930 shares of the company’s stock, valued at approximately $3,157,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Assenagon Asset Management S.A. raised its stake in Evolus by 51.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 908,180 shares of the company’s stock worth $6,303,000 after acquiring an additional 310,035 shares during the last quarter. Perceptive Advisors LLC purchased a new stake in Evolus during the 1st quarter valued at about $5,289,000. Rice Hall James & Associates LLC acquired a new position in shares of Evolus in the second quarter valued at about $8,952,000. Pinnacle Associates Ltd. increased its holdings in shares of Evolus by 15.9% in the fourth quarter. Pinnacle Associates Ltd. now owns 782,365 shares of the company’s stock valued at $5,203,000 after purchasing an additional 107,490 shares during the period. Finally, Potomac Capital Management Inc. purchased a new position in shares of Evolus in the fourth quarter worth about $939,000. 90.69% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Weiss Ratings upgraded shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. Wall Street Zen upgraded shares of Evolus from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. BTIG Research restated a “buy” rating and set a $13.00 target price on shares of Evolus in a research report on Wednesday, June 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price target on shares of Evolus in a report on Tuesday. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.50.

Evolus Trading Down 2.2%

Shares of EOLS stock opened at $8.78 on Thursday. Evolus, Inc. has a 12-month low of $3.86 and a 12-month high of $9.12. The business’s 50 day moving average is $6.95 and its two-hundred day moving average is $5.86. The company has a market capitalization of $579.92 million, a P/E ratio of -16.88 and a beta of 1.35.

Evolus Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.